LPTX Leap Therapeutics Company Short-Term Debt

leaptx.com - graphic logo of issuer LPTX

Leap Therapeutics, Inc. (LPTX) focuses on bringing the DKN-01 antibody to market through alliances with pharmaceutical giants. The company's revenues will be based on the commercial implementation of divacilibumab for the treatment of solid tumors. High demand in the targeted therapy segment opens broad licensing opportunities. The company's current liabilities demonstrate borrowing dynamics, while the 0.00 indicator confirms the current level of debt load.

LPTX Leap Tx Short-Term Debt (07/04/2022 - 11/13/2025)

Analytical breakdowns and data insights for company Leap Therapeutics Inc (LPTX)

- current quotes and average value forecast:
Price Chart Leap Tx|LPTX - Average Forecast Price
- market capitalization data:
Market Value Leap Therapeutics, Inc.|LPTX - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share Leap Therapeutics|LPTX - Total Stockholders' Equity|Market Capitalization to Book Value Ratio leaptx.com|LPTX - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Leap Therapeutics, Inc.|LPTX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Leap Tx|LPTX - Aggregate Debt Obligations|Debts to Book Capitalization Leap Therapeutics, Inc.|LPTX - Long-Term Debt Volume|Company Short-Term Debt Leap Therapeutics|Quick Liquidity leaptx.com
- earnings and multiples data:
LPTX - Net Income
General company analysis:leaptx.com (LPTX)
Flagship merchandise of Leap Therapeutics, Inc.

Short-term debt measures a company's obligations with a maturity horizon of up to one year, allowing an investor to assess liquidity risk and the probability of a cash shortfall via a short-term debt chart. Monitoring this metric is critical for Leap Therapeutics, Inc. (LPTX), as stable financing ensures the development of proprietary protocols and the protection of intellectual property during the creation of DKN-01 antibodies in the immuno-oncology sector.

Competitors of Leap Therapeutics, Inc.

IBRX - Company Short-Term Debt|Short-Term Debt Immunocore Holdings|Janux Pharma (JANX) - Company Short-Term Debt|RCUS (Arcus Corp) - Company Short-Term Debt|Company Short-Term Debt Zymeworks Inc.|Short-Term Debt tangotx.com TNGX|Company Short-Term Debts IOVA|Immatics NV (IMTX) - Short-Term Indebtedness|Xencor Corp - Company Current Liabilities|Compass Therapeutics Corp (CMPX) - Short-Term Debt|REPL: Company Current Liabilities|Company Short-Term Loans and Borrowings LYEL (lyell.com)|IPHA: Company Short-Term Debts|PYXS - Short-Term Debt Volume|Company Short-Term Debt Compugen Ltd|Company Current Liabilities IO Biotech Inc. (IOBT)|Company Short-Term Debt Sutro Biopharma, Inc. (STRO)|Company Current Liabilities minktherapeutics.com INKT|Werewolf Therapeutics, Inc. - Company Current Liabilities|Company Short-Term Debts Immix Biopharma Inc. IMMX|ALXO - Company Short-Term Debt|CUE (Cue Biopharma Inc.) - Company Short-Term Indebtedness|pdsbiotech.com (PDSB) - Company Short-Term Debt|Short-Term Debt Sonnet BioTherapeutics Holdings (SONN)|Company Current Liabilities MAIA|LIMN - Short-Term Indebtedness|Company Current Liabilities LVTX (LAVA Therapeutics N.V.)|Amount of Current Liabilities NXTC|Company Short-Term Debts INTS (Intensity Therapeutics, Inc.)|Company Short-Term Loans and Borrowings SNSE|Theriva Biologics - Company Short-Term Debts|Short-Term Debt Gritstone bio, Inc.|Kineta Bio (KA) - Company Short-Term Debt|NexImmune Corporation - Company Short-Term Loans and Borrowings|TSBX (Turnstone Biologics Corp) - Company Short-Term Debts|Company Short-Term Debts vaccinex.com|Company Short-Term Debt Harpoon Therapeutics, Inc. (HARP)